scholarly journals Efficacy of physical therapy associated with botulinum toxin type A on functional performance in post-stroke spasticity: A randomized, double-blinded, placebo-controlled trial

2018 ◽  
Vol 10 (2) ◽  
Author(s):  
Antonio Prazeres ◽  
Marília Lira ◽  
Paula Aguiar ◽  
Larissa Monteiro ◽  
Ítalo Vilasbôas ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Physical Therapy ◽  
Functional Performance ◽  
Controlled Trial ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Upper Limbs ◽  
Post Stroke ◽  
Double Blinded

The aim was to investigate if botulinum toxin type A (BTx-A) associated with physical therapy is superior to physical therapy alone in post stroke spasticity. A randomized, double-blinded controlled trial was performed in a rehabilitation unit on Northeastern, Brazil. Patients with post stroke spasticity were enrolled either to BTx-A injections and a pre-defined program of physical therapy or saline injections plus physical therapy. Primary endpoint was functional performance evaluated through time up and go test, six minutes walking test and Fugl-Meyer scale for upper limb. Secondary endpoint was spasticity improvement. Confidence interval was considered at 95%. Although there was a significant decrease in upper limbs flexor tonus (P<0.05) in the BTx-A group, there was no difference regarding functional performance after 9 months of treatment. When analyzing gait speed and performance, both groups showed a significant improvement in the third month of treatment, however it was not sustained over time. Although BTx-A shows superiority to improve muscle tone, physical therapy is the cornerstone to improve function in the upper limbs of post stroke patients.

scholarly journals Botulinum toxin type A for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial

2014 ◽  
Vol 6 (4) ◽  
Author(s):  
Luciano Hollanda ◽  
Larissa Monteiro ◽  
Ailton Melo
Keyword(s):  
Botulinum Toxin ◽  
Chronic Migraine ◽  
Controlled Trial ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Efficacy Analysis ◽  
Scale Scores ◽  
Efficacy Measures ◽  
Double Blinded

Cephalic allodynia (CA) can be observed in 50-70% of patients with chronic migraine (CM). The aim of this trial was to assess the efficacy of botulinum toxin type A (Botx-A) in the treatment of CA associated with CM. In this placebo-controlled trial, patients were randomized either into Botx-A or 0.9% saline injections and efficacy measures were assessed every 4 weeks for 3 months. Efficacy endpoints were number of migraine episodes associated with CA, changes from baseline in visual analogical scale scores for pain (VAS) and frequency of common analgesics use for migraine. A total of 38 subjects were randomized to saline (n=18) or Botx-A (n=20). There were no significant differences in baseline between active intervention or placebo groups regarding mean age, number of headache episodes [mean 12.1 (9.22) and 17.00 (9.69) respectively; P=0.12], pain severity as measured by the VAS or frequency of analgesic use for headache episodes. Efficacy analysis showed that Botx-A injections led to an important decrease from baseline in the mean migraine episodes associated with CA after 12 weeks (5.20 versus 11.17; P=0.01). Also, VAS scores and frequency of analgesics use for headache were significantly reduced in the Botx-A group. This study suggests that Botx-A injections are superior to saline in the treatment of CA associated with CM, with mild self limited side effects.

Botulinum Toxin Type A and Post-stroke Spasticity of the Upper Limbs

US Neurology ◽  
2009 ◽  
Vol 05 (01) ◽  
pp. 38
Author(s):  
Cindy B Ivanhoe ◽  
Natasha K Eaddy-Rose ◽  
◽  
Keyword(s):  
Botulinum Toxin ◽  
Upper Limb ◽  
Daily Living ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Upper Limbs ◽  
Post Stroke ◽  
The Us ◽  
Developed Nations

Background:Stroke is a significant contributor to morbidity and mortality in the US and other developed nations. Stroke and its side effects are the primary cause of disability in the US and worldwide. Upper limb mobility factors are particularly detrimental to activities of daily living. Successful treatments to improve post-stroke spasticity are required.Objective:To assess the relevant medical literature related to the use of botulinum toxin type A and post-stroke spasticity of the upper limb.Methods:Literature review utilizing Medline with keywords of botulinum toxin, stroke, spasticity, and upper extremity since 2003.Results:Thirteen criteria-based articles investigated botulinum toxin type and poststroke spasticity of the upper limbs. Discussion: Botulinum toxin type A is an effective agent in reducing post-stroke spasticity of the upper limbs.

scholarly journals Physical therapy and adjunctive botulinum toxin type A in the treatment of cervical headache: a double-blind, randomised, placebo-controlled study

2002 ◽  
Vol 3 (2) ◽  
pp. 93-99 ◽  
Author(s):  
Peter Schnider ◽  
Ecaterina Moraru ◽  
Marion Vigl ◽  
Christian Wöber ◽  
Daniela Földy ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Physical Therapy ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Controlled Study ◽  
Double Blind

scholarly journals Access to Focal Spasticity Care: A Cross Canada Survey of Physiatrists

2020 ◽  
Vol 47 (6) ◽  
pp. 834-838
Author(s):  
Kevin E. Liang ◽  
Pham Vivian Ngo ◽  
Paul Winston
Keyword(s):  
Botulinum Toxin ◽  
Physical Therapy ◽  
Occupational Therapy ◽  
Quality Care ◽  
Botulinum Toxin Type A ◽  
Wait Time ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Successful Management

ABSTRACT:Successful management of focal spasticity requires access to botulinum toxin type A (BoNT-A) injections, physiotherapy, occupational therapy, and orthoses/bracing. To assess the quality of focal spasticity care across Canada, we sent a survey consisting of 22 questions to physiatrists involved in the management of outpatient spasticity. Thirty-four physiatrists from all 10 provinces responded to the survey. Wait time for BoNT-A treatment averaged 12.7 weeks from time of referral across Canada. More than 75% of patients faced barriers to obtaining physical therapy and orthoses. Access to best quality care for spasticity patients across Canada varies widely.

Sign in / Sign up

Export Citation Format

Share Document